Anhedonia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Even though prevalence of depression is very high, anti-depressant do not work in the 50% of population. The mechanism of all available anti-depressants is same. More research needs to be done to explore new therapies to tackle anhedonia. | Even though prevalence of depression is very high, anti-depressant do not work in the 50% of population. The mechanism of all available anti-depressants is same. More research needs to be done to explore new therapies to tackle anhedonia, symptoms of depression and brain function. | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Revision as of 22:40, 19 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Overview
Even though prevalence of depression is very high, anti-depressant do not work in the 50% of population. The mechanism of all available anti-depressants is same. More research needs to be done to explore new therapies to tackle anhedonia, symptoms of depression and brain function.
Future or Investigational Therapies
Drugs that mimic melanocortin are avaible and they can be tested to relieve symptoms of anhedonia. Clinical studies needs to explore role of melanocortin in the treatment of anhedonia. Treatment of anhedonia can benefit the patients suffering from depression, schizophrenia and terminally ill patients who ave given up hope.[1]
References
- ↑ "http://med.stanford.edu/ism/2012/july/malenka.html". External link in
|title=(help)